Patient-derived xenografts and organoids model therapy response in prostate cancer
Open Access
- 18 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 12 (1), 1-13
- https://doi.org/10.1038/s41467-021-21300-6
Abstract
Therapy resistance and metastatic processes in prostate cancer (PCa) remain undefined, due to lack of experimental models that mimic different disease stages. We describe an androgen-dependent PCa patient-derived xenograft (PDX) model from treatment-naïve, soft tissue metastasis (PNPCa). RNA and whole-exome sequencing of the PDX tissue and organoids confirmed transcriptomic and genomic similarity to primary tumor. PNPCa harbors BRCA2 and CHD1 somatic mutations, shows an SPOP/FOXA1-like transcriptomic signature and microsatellite instability, which occurs in 3% of advanced PCa and has never been modeled in vivo. Comparison of the treatment-naïve PNPCa with additional metastatic PDXs (BM18, LAPC9), in a medium-throughput organoid screen of FDA-approved compounds, revealed differential drug sensitivities. Multikinase inhibitors (ponatinib, sunitinib, sorafenib) were broadly effective on all PDX- and patient-derived organoids from advanced cases with acquired resistance to standard-of-care compounds. This proof-of-principle study may provide a preclinical tool to screen drug responses to standard-of-care and newly identified, repurposed compounds.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_189149)
- KWF Kankerbestrijding (2015_7599)
- Novartis (17B076)
This publication has 70 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 InactivationCancer Research, 2012
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancerNature Genetics, 2012
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesionsJournal of Translational Medicine, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2011
- The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancersCanadian Urological Association Journal, 2011
- EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for TreatmentPharmaceuticals, 2010
- Establishment and Genomic Characterization of Mouse Xenografts of Human Primary Prostate TumorsThe American Journal of Pathology, 2010
- BM18: A novel androgen-dependent human prostate cancer xenograft model derived from a bone metastasisThe Prostate, 2005